Latest Headlines
-
The Jackson Laboratory And AbTherx Announce Partnership To Enhance Therapeutic Antibody Discovery
5/10/2024
The Jackson Laboratory (JAX), an independent, nonprofit biomedical research organization, and AbTherx, an innovator in biotechnology, announced a strategic partnership to develop and commercialize cutting-edge tools to expedite antibody discovery and derisk the development of vital new therapies.
-
Würzburg Researchers Discover New Function Of Oncoproteins
5/8/2024
Researchers at the University of Würzburg have discovered a new function of the oncoprotein MYCN: It not only helps cancer cells to grow stronger, but also makes them more resistant to drugs.
-
Avicenna Introduces Machine Learning-Enhanced Medicinal Chemistry Platform To Accelerate The Last Mile Of Small Molecule Drug Discovery
5/8/2024
Avicenna Biosciences today introduced an extension to its machine learning (ML) technology platform to enhance medicinal chemistry and expedite clinical-stage drug discovery.
-
Rakovina Therapeutics Announces Extensions And Expansions Of Strategic Collaborations To Support AI Research
5/8/2024
Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the expansion of two research collaborations to align with its recently announced collaboration with the Deep Docking AI Drug Discovery Platform.
-
Biotheryx Announces U.S. FDA Clearance Of Investigational New Drug Application For BTX-9341, A First-In-Class, Dual Bifunctional Degrader Of CDK4/6
5/7/2024
Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on validated targets in cancer and inflammatory disease, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for BTX-9341, a novel cyclin-dependent kinase 4/6 (CDK4/6) bifunctional degrader.
-
Selvita Completes Acquisition Of PozLab And Significantly Expands Its Drug Development Capabilities
5/7/2024
Selvita S.A. [WSE: SLV] announced today completion of a strategic transaction in which it has acquired 100% of shares in PozLab. The closing of the transaction comes shortly after the announcement of the transaction on March 27, 2024.
-
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration To Optimize Development Of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor Of Cancer Metabolism
5/6/2024
Lantern Pharma Inc. a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase (PDI)(1) inhibitor drug candidate XCE853 in novel and targeted cancer indications.
-
Convenience Meets Compliance: Introducing The Next-Generation Sterility Testing Pump For The Connected Lab
5/6/2024
The life science group Sartorius announces the launch of the 4th generation Sterisart® Universal pump, marking a significant innovation in the field of sterility testing. Designed for the reliable transfer of samples and media into Sterisart® canisters, this new pump meets the stringent quality and safety standards demanded by today's pharmaceutical and biotechnology industries.
-
Researchers Develop New AI Tool For Fast And Precise Tissue Analysis To Support Drug Discovery And Diagnostics
5/6/2024
A team of scientists from A*STAR’s Genome Institute of Singapore (GIS) and Bioinformatics Institute (BII) have developed a new AI software tool called “BANKSY” that automatically recognises the cell types present in a tissue, such as muscle cells, nerve cells and fat cells. Going a step beyond conventional AI tools which can group cells together into clusters if they contain similar molecules, BANKSY also considers how similar the cells' surroundings in the tissue are.
-
U.S. Food And Drug Administration Accepts Bristol Myers Squibb’s Application For Subcutaneous Nivolumab (nivolumab And hyaluronidase)
5/6/2024
Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for the subcutaneous formulation of Opdivo (nivolumab) co-formulated with Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20) (herein referred to as “subcutaneous nivolumab”) across all previously approved adult, solid tumor Opdivo indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy (ipilimumab) combination therapy, or in combination with chemotherapy or cabozantinib.